Imunofan, 1 piece, 8.5 ml, 45 mcg/dose, metered nasal spray

Composition and release form

in blister packs 5 or 10 ampoules; in a cardboard pack 1 or 2 packages.

in blister packs 5 or 10 pcs.; in a cardboard pack 1 or 2 packages.

in a plastic bottle with a dosing device 8.5 ml; 1 bottle in a cardboard pack.

Pharmacodynamics

The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radicals and peroxide compounds. Corrects the state of the immune system, restores the balance of the body's oxidative-antioxidative reactions and helps overcome multidrug resistance of tumor cells, mediated by proteins of the cell's transmembrane transport pump.

The effect of the drug begins to develop within 2–3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

During the fast phase (duration - up to 2-3 days), the detoxification effect is manifested primarily - the body's antioxidant defense is enhanced due to stimulation of the production of ceruloplasmin, lactoferrin, and catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, with a subsequent reduction in blood cholesterol levels and the production of inflammatory mediators. In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.

During the middle phase (begins after 2-3 days, duration - up to 7-10 days), the reactions of phagocytosis and death of intracellular bacteria and viruses intensify.

During the slow phase (begins to develop on 7–10 days, duration up to 4 months), the immunoregulatory effect of Imunofan® is manifested - restoration of impaired indicators of cellular and humoral immunity. During this period, normalization of the immunoregulatory index is observed, and an increase in the production of specific antibodies is noted. The effect of the drug on the production of specific antiviral and antibacterial antibodies is equivalent to the effect of therapeutic vaccines. Unlike the latter, the drug does not have a significant effect on the production of reagin antibodies of the IgE class and does not enhance the immediate hypersensitivity reaction; Imunofan® stimulates the formation of IgA in case of congenital deficiency.

Imunofan® effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the effects of chemotherapy drugs.

How does the medication work?

Imunofan has a general strengthening, detoxifying effect, functions as a hepatoprotector, and has antioxidant properties. Under its influence, the development of pathogen resistance to antibiotics and the development of superinfections slow down, intracellular metabolism is restored, and the processes of antibody production are normalized.

In the first hours and days from the start of use, Imunofan exhibits powerful antioxidant properties and provides detox:

• protects hepatocytes from the destructive effects of pathogens;
• prevents the breakdown of healthy cells;
• prevents tissue damage from free radicals and drug metabolites;
• improves blood laboratory parameters, reduces cholesterol levels.

Patients experience some relief of symptoms: decreased fever, headaches, improved appetite.

From 3–4 days of therapy, an antiviral effect develops: the concentration of pathogens in the body decreases, normal health is restored.

The long-term effect of using Imunofan is observed after 1–4 months of regular administration. Humoral and cellular immunity is strengthened, clinical signs of their deficiency disappear, the concentration of IgA class antibodies increases, which ensure that the body “meets” foreign proteins. At the same time, the level of specific antibodies increases. During oncological processes, the sensitivity of altered cells to chemotherapy increases. Long courses of Imunofan are comparable to the effectiveness of vaccination.

Indications of the drug Imunofan®

Solution for intramuscular and subcutaneous administration and rectal suppositories

For adults and children over 2 years of age (prevention and treatment):

immunodeficiency and toxic conditions;

chronic inflammatory diseases of various etiologies.

For adults - as an adjuvant for vaccination against bacterial and viral infections.

Dosed nasal spray:

For adults and children over 2 years of age (prevention and treatment):

immunodeficiency and toxic conditions;

acute and chronic infectious and inflammatory diseases.

Directions for use and doses

SC or IM, rectally, intranasally.

Injection:

courses, single and daily dose - 50 mcg.

Suppositories:

single (daily) dose - 100 mcg (1 supp.).

Nasal spray:

When using, the bottle should be held vertically, with the sprayer facing up. Remove the protective cap from the sprayer. Before first use, fill the dosing pump by pressing the wide rim of the spray nozzle 3-4 times. Insert the sprayer into the nasal passage with the head in a vertical position. Press the wide rim of the spray nozzle once until it stops. One dose of the drug contains 50 mcg of imunofan. The daily dose should not exceed 200 mcg.

When treating cancer patients in a radical combination treatment regimen (chemoradiation therapy and surgery):

— 1 time per day, daily, course of treatment — 8–10 injections (8–10 supp. or 1 dose in each nasal passage for 8–10 days) before chemoradiotherapy and surgery, followed by repetition of courses throughout the entire treatment period , with a break of 15–20 days.

In patients with an advanced tumor process (stages III–IV) of various localizations in the form of complex or symptomatic therapy:

- 1 time per day, daily, course of treatment - 8-10 injections (8-10 supp. or 1 dose in each nasal passage for 8-10 days), with a break of 15-20 days and repeating courses throughout period of subsequent treatment.

In children with malignant diseases of the hematopoietic and lymphoid systems:

- 1 time per day, daily, course of treatment - 10-20 injections (10-20 supp.). The drug is prescribed throughout the course of chemoradiotherapy and after its completion to prevent the development of toxicosis.

In the complex therapy of acute and chronic infectious and inflammatory diseases accompanied by symptoms of intoxication and immunodeficiency:

- 1 dose (50 mcg) in each nasal passage 2 times a day, daily for 10–15 days.

In complex therapy of children with papillomatosis of the larynx and oropharynx:

— 1 time per day, daily, course of treatment — 10 injections (10 supp.).

For opportunistic infections (CMV and herpes infections, toxoplasmosis, chlamydia, pneumocystis, cryptosporidiosis):

— 1 time a day, daily, course of treatment — 15–20 injections (15–20 supp.) or 1 dose in each nasal passage 2 times a day, daily, course of treatment — 10–15 days. If necessary, courses can be repeated after 2–4 weeks.

In complex therapy of HIV infection:

— 1 time per day, daily, course of treatment — 15–20 injections (15–20 supp. or 1 dose in each nasal passage for 10–15 days). If necessary, it is possible to conduct repeated courses after 2–4 weeks.

For chronic viral hepatitis and chronic brucellosis:

- 1 time per day, daily, course of treatment - 15-20 injections (15-20 sup. or 1 dose in each nasal passage for 10-15 days), to prevent relapses, repeated courses should be carried out after 2-3 months ( for nasal spray - after 4–6 months).

For diphtheria:

- 1 time per day, daily, course of treatment - 8-10 injections (8-10 supp.). For diphtheria bacteria carriage - 1 time every 3 days. The course of treatment is 3–5 injections (3–5 supp.).

In the treatment of III-IV degree burns with symptoms of toxemia, septicotoxemia, in surgical patients with septic endocarditis, long-term non-healing wounds of the extremities, purulent-septic complications:

- 1 time per day, daily, course of treatment - 7-10 injections (7-10 supp.), if necessary, the course of treatment should be continued up to 20 injections (20 supp.).

For broncho-obstructive syndrome, cholecystopancreatitis, rheumatoid arthritis:

- 1 time every 3 days, course of treatment - 8-10 injections (8-10 supp.), if necessary, the course of treatment should be continued up to 20 injections (20 supp.) according to the same scheme.

When treating psoriasis:

— 1 time per day, daily, course of treatment — 15–20 injections (15–20 supp.).

Vaccinal prevention:

adults - once on the day of vaccination.

Imunofan, spray naz.50mkg/dose fl.40doses (Bionox (Moscow), RUSSIA)

Composition and release form.

in blister packs 5 or 10 ampoules; in a cardboard pack 1 or 2 packages.

in blister packs 5 or 10 pcs.; in a cardboard pack 1 or 2 packages.

in a plastic bottle with a dosing device 8.5 ml; 1 bottle in a cardboard pack.

Description of the dosage form.

Injection:

colorless transparent liquid.

Suppositories:

homogeneous suppositories from white to white with a yellowish tint, torpedo-shaped. A slight specific odor is allowed.

Nasal spray:

clear or slightly opalescent colorless or slightly yellowish liquid.
A slight specific odor is allowed. Pharmachologic effect. Immunomodulatory, antioxidant, hepatoprotective, detoxifying.

Pharmacodynamics.

The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radicals and peroxide compounds. Corrects the state of the immune system, restores the balance of the body's oxidative-antioxidative reactions and helps overcome multidrug resistance of tumor cells, mediated by proteins of the cell's transmembrane transport pump.

The effect of the drug begins to develop within 2–3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

During the fast phase (duration - up to 2-3 days), the detoxification effect is manifested primarily - the body's antioxidant defense is enhanced due to stimulation of the production of ceruloplasmin, lactoferrin, and catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, with a subsequent reduction in blood cholesterol levels and the production of inflammatory mediators. In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.

During the middle phase (begins after 2-3 days, duration - up to 7-10 days), the reactions of phagocytosis and death of intracellular bacteria and viruses intensify.

During the slow phase (begins to develop on 7–10 days, duration up to 4 months), the immunoregulatory effect of Imunofan® is manifested - restoration of impaired indicators of cellular and humoral immunity. During this period, normalization of the immunoregulatory index is observed, and an increase in the production of specific antibodies is noted. The effect of the drug on the production of specific antiviral and antibacterial antibodies is equivalent to the effect of therapeutic vaccines. Unlike the latter, the drug does not have a significant effect on the production of reagin antibodies of the IgE class and does not enhance the immediate hypersensitivity reaction; Imunofan® stimulates the formation of IgA in case of congenital deficiency.

Imunofan® effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the effects of chemotherapy drugs.

Indications.

Solution for intramuscular and subcutaneous administration and rectal suppositories

For adults and children over 2 years of age (prevention and treatment):

● immunodeficiency and toxic conditions;

● chronic inflammatory diseases of various etiologies.

For adults - as an adjuvant for vaccination against bacterial and viral infections.

Dosed nasal spray:

For adults and children over 2 years of age (prevention and treatment):

● immunodeficiency and toxic conditions;

● acute and chronic infectious and inflammatory diseases.

Contraindications.

● hypersensitivity;

● children under 2 years of age.

For solution for intramuscular and subcutaneous administration and rectal suppositories

(additional) - pregnancy complicated by Rh conflict.

Use during pregnancy and breastfeeding.

Solution for intramuscular and subcutaneous administration and rectal suppositories

Contraindicated in pregnancy complicated by Rhesus conflict.

Due to insufficient knowledge, nasal spray

should be used with caution during pregnancy and lactation.

Side effects.

Individual intolerance is possible.

Interaction.

For all dosage forms:

combination with anti-inflammatory (steroidal and non-steroidal) drugs is possible (the effect of Imunofan® does not depend on the production of PGE2).

Injection:

There have been no cases of interaction of Imunofan® with other drugs.

Nasal spray:

increases the effectiveness of other types of drug therapy; the use of imunofan helps overcome resistance to GCS therapy.

Method of administration and dose.

SC or IM, rectally, intranasally.

Injection:

courses, single and daily dose - 50 mcg.

Suppositories:

single (daily) dose - 100 mcg (1 supp.).

Nasal spray:

When using, the bottle should be held vertically, with the sprayer facing up. Remove the protective cap from the sprayer. Before first use, fill the dosing pump by pressing the wide rim of the spray nozzle 3-4 times. Insert the sprayer into the nasal passage with the head in a vertical position. Press the wide rim of the spray nozzle once until it stops. One dose of the drug contains 50 mcg of imunofan. The daily dose should not exceed 200 mcg.

When treating cancer patients in a radical combination treatment regimen (chemoradiation therapy and surgery):

— 1 time per day, daily, course of treatment — 8–10 injections (8–10 supp. or 1 dose in each nasal passage for 8–10 days) before chemoradiotherapy and surgery, followed by repetition of courses throughout the entire treatment period , with a break of 15–20 days.

In patients with an advanced tumor process (stages III–IV) of various localizations in the form of complex or symptomatic therapy:

- 1 time per day, daily, course of treatment - 8-10 injections (8-10 supp. or 1 dose in each nasal passage for 8-10 days), with a break of 15-20 days and repeating courses throughout period of subsequent treatment.

In children with malignant diseases of the hematopoietic and lymphoid systems:

- 1 time per day, daily, course of treatment - 10-20 injections (10-20 supp.). The drug is prescribed throughout the course of chemoradiotherapy and after its completion to prevent the development of toxicosis.

In the complex therapy of acute and chronic infectious and inflammatory diseases accompanied by symptoms of intoxication and immunodeficiency:

- 1 dose (50 mcg) in each nasal passage 2 times a day, daily for 10–15 days.

In complex therapy of children with papillomatosis of the larynx and oropharynx:

— 1 time per day, daily, course of treatment — 10 injections (10 supp.).

For opportunistic infections (CMV and herpes infections, toxoplasmosis, chlamydia, pneumocystis, cryptosporidiosis):

— 1 time a day, daily, course of treatment — 15–20 injections (15–20 supp.) or 1 dose in each nasal passage 2 times a day, daily, course of treatment — 10–15 days. If necessary, courses can be repeated after 2–4 weeks.

In complex therapy of HIV infection:

— 1 time per day, daily, course of treatment — 15–20 injections (15–20 supp. or 1 dose in each nasal passage for 10–15 days). If necessary, it is possible to conduct repeated courses after 2–4 weeks.

For chronic viral hepatitis and chronic brucellosis:

- 1 time per day, daily, course of treatment - 15-20 injections (15-20 sup. or 1 dose in each nasal passage for 10-15 days), to prevent relapses, repeated courses should be carried out after 2-3 months ( for nasal spray - after 4–6 months).

For diphtheria:

- 1 time per day, daily, course of treatment - 8-10 injections (8-10 supp.). For diphtheria bacteria carriage - 1 time every 3 days. The course of treatment is 3–5 injections (3–5 supp.).

In the treatment of III-IV degree burns with symptoms of toxemia, septicotoxemia, in surgical patients with septic endocarditis, long-term non-healing wounds of the extremities, purulent-septic complications:

- 1 time per day, daily, course of treatment - 7-10 injections (7-10 supp.), if necessary, the course of treatment should be continued up to 20 injections (20 supp.).

For broncho-obstructive syndrome, cholecystopancreatitis, rheumatoid arthritis:

- 1 time every 3 days, course of treatment - 8-10 injections (8-10 supp.), if necessary, the course of treatment should be continued up to 20 injections (20 supp.) according to the same scheme.

When treating psoriasis:

— 1 time per day, daily, course of treatment — 15–20 injections (15–20 supp.).

Vaccinal prevention:

adults - once on the day of vaccination.

Special instructions.

As a result of activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, maintained due to the persistence of viral or bacterial antigens, is possible.